04:43 PM EDT, 08/12/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) reported Q2 earnings late Tuesday of $1.21 per diluted share, swinging from a loss of $0.48 a year earlier.

Analysts surveyed by FactSet expected earnings of $2.03.

Revenue for the quarter ended June 30 was $25.9 million, up from $4.5 million a year earlier.

Analysts polled by FactSet expected $22.6 million.

Zevra said it has sufficient resources and financial flexibility to execute on its strategic priorities independent from the capital markets. Its cash, cash equivalents and securities were $217.7 million at the end of June.

Shares were down about 6% during after-hours trading.